Publication date: Jul 16, 2025
A recent phase 2b clinical trial in South Africa found that Bacille Calmette-Gurin (BCG) revaccination did not prevent sustained Mycobacterium tuberculosis infection in initially uninfected, HIV-negative adolescents. The participants were randomly assigned to receive either the BCG vaccine (918 individuals) or a placebo (917 individuals). The BCG group also experienced a higher rate of adverse events, though these were primarily mild and localized injection-site reactions such as redness, swelling, pain, and occasional ulceration. The calculated hazard ratio was 1. 04 (95% CI, 0. 73 to 1. 48), by indicating essentially no difference between the vaccine and placebo groups. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection. The New England Journal of Medicine, 392(18), 17891800. https://doi. org/10. 1056/nejmoa2412381
| Concepts | Keywords |
|---|---|
| Adolescents | Adolescents |
| Tuberculosis | Bcg |
| Vaccination | Clinical |
| Efficacy | |
| Hiv | |
| Infection | |
| Negative | |
| Phase | |
| Placebo | |
| Qft | |
| Revaccination | |
| Sustained | |
| Trial | |
| Tuberculosis | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | site |
| disease | IDO | immune response |
| disease | MESH | latent infections |
| disease | IDO | assay |
| pathway | REACTOME | Release |
| pathway | KEGG | Tuberculosis |
| disease | MESH | Mycobacterium tuberculosis infection |
| disease | MESH | Infection |
| drug | DRUGBANK | BCG vaccine |